NCT Number: NCT00217958
Better Asthma Outcomes: Lowering Tobacco Smoke Exposure
To improve disease outcomes through reduction in secondhand tobacco smoke exposure of children with asthma
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–12 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
About this study
BACKGROUND:
Secondhand tobacco smoke (SHS) exposure increases asthma morbidity in children. Efforts to reduce exposure have had mixed results. This study is a randomized controlled trial of an exposure reduction intervention, with objective feedback to parents on the child's exposure based on urine cotinine measurement, and counseling tailored to the child's specific exposure sources/locations and parental readiness to take specific actions to reduce exposure from each source/location. This trial involves 350 SHS-exposed children with persistent asthma, 3-12 years of age, receiving care from the Kaiser Health Care Program in Northern California. Primary outcomes over the 18 months of follow-up will be asthma acute care utilization and urine cotinine/creatine ratio. Changes in controller medication adherence will be evaluated using a pharmacy-based dispensing index.
DESIGN NARRATIVE:
Primary objective: To evaluate the efficacy of a behaviorally-based, cotinine-feedback-and-monitoring program designed to reduce SHS exposure in an 18-month randomized controlled trial (RCT) with 350 children with persistent asthma, 3-12 years of age, in comparison with usual medical care.
Secondary objectives: 1) to investigate the behavioral mechanisms that mediate between the intervention and associated improvements in asthma outcomes, and 2) to determine the influence of initial caregiver stage of change with regard to smoking practices on response to the intervention.
Hypotheses:
- Disease outcomes: A behaviorally-based, individually-tailored intervention that emphasizes SHS exposure reduction, provides sequential feedback to the parent on the child's urine cotinine level, and is tailored to the parent's stage of change with regard to smoking practices will be associated with decreased asthma crisis care utilization and improvements in secondary disease outcomes over an 18-month follow-up period when compared with usual medical care.
- ETS exposure: The SHS reduction intervention will be associated with lower SHS exposure at follow-up (assessed by urine cotinine/creatinine ratio), compared with usual medical care.
- Mechanism: Decreases in urine cotinine/creatinine ratio will be instrumental in intervention-associated improvements in asthma crisis care utilization.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
- Age 3-12 years
- Kaiser member for >= 1 year
- >= 1 asthma care visit in prior year
- Persistent asthma likely based on prior year:
Physician diagnosis code of persistent asthma OR >= 4 beta agonist (BA) dispensing events OR >= 4 Anti-inflammatory (AI) dispensing events
- Secondhand smoke exposure by parent report.
- Parent agrees to participate in a clinical trial of a smoke exposure reduction interventio
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Palo Alto Medical Foundation
Other
Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Registry information
Important dates
- Study start
- 2002
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- Sep 22, 2005
- Registry last updated
- Oct 28, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Histoblood Group Antigens as a Risk Factor of Asthma
NCT00201266
Asthma, Bronchial Diseases
San Francisco, California, United States
View Trial DetailsDaily Vitamin D for Sickle-cell Respiratory Complications
NCT04170348
Acute Chest Syndrome, Anemia
New York, United States
View Trial DetailsIndividualizing Treatment for Asthma in Primary Care
NCT06272370
Asthma, Bronchial Diseases
Aurora, Colorado, United States
View Trial DetailsInterventions to Improve Asthma Management/Prevention at School
NCT00005736
Asthma, Bronchial Diseases
View Trial Details